Home › Funds › Continuum Advisory, LLC › BMRN
Continuum Advisory, LLC position in BMRN
BIOMARIN PHARMACEUTICAL INC · Health Care
Continuum Advisory, LLC reported holding 101,850 shares of BMRN (BIOMARIN PHARMACEUTICAL INC) in its Q3 2026 13F filing — a position valued at US$6.1M, representing 0.50% of its reported portfolio and ranking #39 among its reported holdings. Continuum Advisory, LLC has disclosed BMRN holdings in 9 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Continuum Advisory, LLC's BMRN position evolved
Continuum Advisory, LLC first disclosed a stake in BMRN in Q1 2024 at 35 shares (US$3K). The position peaked in Q3 2026 at 101,850 shares, worth US$6.1M. Across 9 filings, Continuum Advisory, LLC increased the stake 1 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 101,850 shares valued at US$6.1M — a reduction of -2,642 shares quarter over quarter.. Notable position changes include a 37% trim in Q4 2024 (shares rose 8% over the following quarter), a 35% trim in Q1 2025 (shares fell 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 35 | $2.86K | New |
| Q2 2024 | 35 | $2.88K | Hold |
| Q3 2024 | 27 | $1.77K | Reduce |
| Q4 2024 | 17 | $1.12K | Reduce |
| Q1 2025 | 11 | $778 | Reduce |
| Q4 2025 | 101.42K | $6.03M | New |
| Q1 2026 | 104.54K | $5.91M | Add |
| Q2 2026 | 104.49K | $5.98M | Hold |
| Q3 2026 | 101.85K | $6.11M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BMRN and 13F data
BMRN (BIOMARIN PHARMACEUTICAL INC) is a Health Care company. 26 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$899.3M), Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$435.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BMRN
- PRIMECAP MANAGEMENT CO/CA/ 14.99M sh · $899.34M · Q3 2026
- Viking Global Investors 7.62M sh · $435.82M · Q2 2026
- VIKING GLOBAL INVESTORS LP 7.62M sh · $435.82M · Q2 2026
- Vestal Point Capital, LP 6.03M sh · $344.75M · Q2 2026
- Deep Track Capital, LP 3.31M sh · $189.25M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 111.50M sh · $108.89M · Q2 2026
More on Continuum Advisory, LLC
FAQ
How long has Continuum Advisory, LLC held BMRN?
Continuum Advisory, LLC has disclosed BMRN holdings in 9 of the last 11 reported quarters, going back to Q1 2024.
What is Continuum Advisory, LLC's current position in BMRN?
As of Q3 2026, Continuum Advisory, LLC holds 101.85K shares of BMRN (BIOMARIN PHARMACEUTICAL INC), valued at $6.11M, representing 0.50% of its reported portfolio and ranking #39.
Has Continuum Advisory, LLC been buying or selling BMRN?
In the latest 13F filing (Q3 2026), Continuum Advisory, LLC reduced its position in BMRN. The position peaked in Q3 2026 at 101.85K shares.
Which other funds hold BMRN?
Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, VIKING GLOBAL INVESTORS LP, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.